ALZNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:08):

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders...

Stats
本日の出来高	9 226.00
平均出来高	55 627.00
時価総額	5.08M
EPS	$0 ( 2024-03-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.0130 (1.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Ault Milton C Iii	Buy	1 000	Common Stock
2024-04-01	Ault Milton C Iii	Buy	334	Common Stock
2024-01-05	Ault Milton C Iii	Buy	2 000	Common Stock
2024-03-26	Ault Milton C Iii	Buy	780 000	Warrants
2024-03-26	Ault Milton C Iii	Buy	780	Series B Convertible Preferred Stock

INSIDER POWER
-8.48
Last 96 transactions
Buy: 11 786 230 \| Sell: 5 921 131

Alzamend Neuro, Inc. 相関

10 最も正の相関
SEDG	0.983
IMUX	0.974
CFRX	0.973
RIDE	0.973
BXRX	0.971
ELEV	0.97
BNGO	0.969
IRDM	0.968
FNCH	0.967
RELI	0.967

10 最も負の相関
ADAL	-0.973
SLMBP	-0.973
HCNE	-0.971
VMGA	-0.97
JUGG	-0.967
IXAQ	-0.966
HORI	-0.966
GPAC	-0.966
LCAA	-0.964
IBEX	-0.962

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Alzamend Neuro, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-23 066.00 (0.00 %)
EPS:	$-2.29

FY	2023
収益:	$0
総利益:	$-23 066.00 (0.00 %)
EPS:	$-2.29

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.09

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0594

Financial Reports:

No articles found.

Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.